New selective PAD4 inhibitors binding a calcium-deficient form of the PAD4 enzyme have validated the critical enzymatic part of human and mouse PAD4 in the two histone citrullination and neutrophil extracellular trap development for, to our expertise, the first time. The therapeutic possible of PAD4 inhibitors can now be explored. https://xiaopingx221mxj4.blogdeazar.com/profile